(ICL) ICL Israel Chemicals - Ratings and Ratios
Potash, Phosphate, Bromine, Magnesium, Fertilizers
ICL EPS (Earnings per Share)
ICL Revenue
Description: ICL ICL Israel Chemicals
ICL Israel Chemicals Ltd (NYSE:ICL) is a global specialty minerals and chemicals company operating in four segments: Industrial Products, Potash, Phosphate Solutions, and Growing Solutions. The company produces a range of products, including bromine, potash, phosphate-based fertilizers, and fertilizers for the agriculture industry. ICL serves various industries, including pharmaceuticals, food, oil and gas, and agriculture, and sells its products through marketing companies, agents, and distributors.
From a business perspective, ICLs diversified product portfolio and global presence are key strengths. The companys Industrial Products segment benefits from the production of bromine and bromine-based compounds, which are used in various applications, including flame retardants and pharmaceuticals. The Potash and Phosphate Solutions segments are critical to the agriculture industry, providing essential fertilizers and other products. The Growing Solutions segment is also noteworthy, as it develops and markets fertilizers and other products that cater to the needs of farmers and agronomists. Key Performance Indicators (KPIs) to watch include revenue growth, gross margin, and operating cash flow.
To further analyze ICLs performance, we can examine additional KPIs such as Return on Equity (ROE) of 6.71%, which indicates the companys ability to generate profits from shareholder equity. The companys Market Capitalization of $8.87 billion and Price-to-Earnings (P/E) ratio of 22.16 suggest a relatively stable and profitable business. Other relevant metrics include the companys debt-to-equity ratio, interest coverage ratio, and dividend yield, which can provide insights into its financial health and dividend policy.
ICLs commitment to innovation is evident in its digital platforms and technological solutions for farmers and agronomists, which is a growing area of focus for the company. As the global demand for food production continues to rise, ICLs products and solutions are well-positioned to benefit from this trend. By examining the companys research and development expenses, as well as its partnerships and collaborations, we can gain a better understanding of its innovation pipeline and growth prospects.
ICL Stock Overview
| Market Cap in USD | 8,166m |
| Sub-Industry | Fertilizers & Agricultural Chemicals |
| IPO / Inception | 2014-09-24 |
ICL Stock Ratings
| Growth Rating | 29.5% |
| Fundamental | 46.5% |
| Dividend Rating | 50.1% |
| Return 12m vs S&P 500 | 29.5% |
| Analyst Rating | 3.0 of 5 |
ICL Dividends
| Dividend Yield 12m | 2.95% |
| Yield on Cost 5y | 7.06% |
| Annual Growth 5y | 16.33% |
| Payout Consistency | 67.7% |
| Payout Ratio | 48.3% |
ICL Growth Ratios
| Growth Correlation 3m | -67.1% |
| Growth Correlation 12m | 86.8% |
| Growth Correlation 5y | 3.5% |
| CAGR 5y | -3.73% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.13 |
| Sharpe Ratio 12m | -0.12 |
| Alpha | 46.20 |
| Beta | 0.514 |
| Volatility | 33.02% |
| Current Volume | 458.8k |
| Average Volume 20d | 613.3k |
| Stop Loss | 6 (-3.1%) |
| Signal | 0.67 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (367.0m TTM) > 0 and > 6% of Revenue (6% = 417.2m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -2.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.02% (prev 19.75%; Δ 6.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 1.26b > Net Income 367.0m (YES >=105%, WARN >=100%) |
| Net Debt (2.33b) to EBITDA (1.44b) ratio: 1.62 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.29b) change vs 12m ago 0.15% (target <= -2.0% for YES) |
| Gross Margin 32.29% (prev 32.27%; Δ 0.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 58.97% (prev 63.48%; Δ -4.50pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.05 (EBITDA TTM 1.44b / Interest Expense TTM 277.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.02
| (A) 0.15 = (Total Current Assets 4.24b - Total Current Liabilities 2.43b) / Total Assets 12.38b |
| (B) 0.47 = Retained Earnings (Balance) 5.84b / Total Assets 12.38b |
| (C) 0.07 = EBIT TTM 845.0m / Avg Total Assets 11.79b |
| (D) 0.99 = Book Value of Equity 6.03b / Total Liabilities 6.11b |
| Total Rating: 4.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.50
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 4.22% = 2.11 |
| 3. FCF Margin 6.30% = 1.57 |
| 4. Debt/Equity 0.48 = 2.38 |
| 5. Debt/Ebitda 2.02 = -0.04 |
| 6. ROIC - WACC 0.94% = 1.17 |
| 7. RoE 6.26% = 0.52 |
| 8. Rev. Trend -76.73% = -3.84 |
| 9. Rev. CAGR -10.93% = -1.82 |
| 10. EPS Trend -82.51% = -2.06 |
| 11. EPS CAGR -50.24% = -2.50 |
What is the price of ICL shares?
Over the past week, the price has changed by +1.81%, over one month by +5.10%, over three months by -3.97% and over the past year by +54.18%.
Is ICL Israel Chemicals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ICL is around 6.37 USD . This means that ICL is currently overvalued and has a potential downside of 2.91%.
Is ICL a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ICL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.6 | 6.8% |
| Analysts Target Price | 6.6 | 6.8% |
| ValueRay Target Price | 7 | 12.6% |
Last update: 2025-09-04 04:40
ICL Fundamental Data Overview
CCE Cash And Equivalents = 701.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 21.5862
P/S = 1.1744
P/B = 1.3435
P/EG = 9.44
Beta = 1.185
Revenue TTM = 6.95b USD
EBIT TTM = 845.0m USD
EBITDA TTM = 1.44b USD
Long Term Debt = 2.55b USD (from longTermDebt, last quarter)
Short Term Debt = 365.0m USD (from shortTermDebt, last quarter)
Debt = 2.92b USD (Calculated: Short Term 365.0m + Long Term 2.55b)
Net Debt = 2.33b USD (from netDebt column, last quarter)
Enterprise Value = 10.38b USD (8.17b + Debt 2.92b - CCE 701.0m)
Interest Coverage Ratio = 3.05 (Ebit TTM 845.0m / Interest Expense TTM 277.0m)
FCF Yield = 4.22% (FCF TTM 438.0m / Enterprise Value 10.38b)
FCF Margin = 6.30% (FCF TTM 438.0m / Revenue TTM 6.95b)
Net Margin = 5.28% (Net Income TTM 367.0m / Revenue TTM 6.95b)
Gross Margin = 32.29% ((Revenue TTM 6.95b - Cost of Revenue TTM 4.71b) / Revenue TTM)
Tobins Q-Ratio = 1.72 (Enterprise Value 10.38b / Book Value Of Equity 6.03b)
Interest Expense / Debt = 3.36% (Interest Expense 98.0m / Debt 2.92b)
Taxrate = 27.04% (172.0m / 636.0m)
NOPAT = 616.5m (EBIT 845.0m * (1 - 27.04%))
Current Ratio = 1.75 (Total Current Assets 4.24b / Total Current Liabilities 2.43b)
Debt / Equity = 0.48 (Debt 2.92b / last Quarter total Stockholder Equity 6.01b)
Debt / EBITDA = 2.02 (Net Debt 2.33b / EBITDA 1.44b)
Debt / FCF = 6.66 (Debt 2.92b / FCF TTM 438.0m)
Total Stockholder Equity = 5.86b (last 4 quarters mean)
RoA = 2.97% (Net Income 367.0m, Total Assets 12.38b )
RoE = 6.26% (Net Income TTM 367.0m / Total Stockholder Equity 5.86b)
RoCE = 10.04% (Ebit 845.0m / (Equity 5.86b + L.T.Debt 2.55b))
RoIC = 7.41% (NOPAT 616.5m / Invested Capital 8.32b)
WACC = 6.47% (E(8.17b)/V(11.08b) * Re(7.91%)) + (D(2.92b)/V(11.08b) * Rd(3.36%) * (1-Tc(0.27)))
Shares Correlation 3-Years: 0.0 | Cagr: 0.01%
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.62% ; FCFE base≈524.7m ; Y1≈420.8m ; Y5≈287.2m
Fair Price DCF = 4.13 (DCF Value 5.33b / Shares Outstanding 1.29b; 5y FCF grow -23.71% → 3.0% )
Revenue Correlation: -76.73 | Revenue CAGR: -10.93%
Rev Growth-of-Growth: 17.23
EPS Correlation: -82.51 | EPS CAGR: -50.24%
EPS Growth-of-Growth: 77.05
Additional Sources for ICL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle